TARA

Protara Therapeutics, Inc. [TARA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TARA Stock Summary

Top 10 Correlated ETFs

TARA


Top 10 Correlated Stocks

TARA


In the News

08:00 22 Mar 2023 TARA

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:

08:00 22 Mar 2023 TARA

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 11:20 am ET in New York, New York.

11:00 22 Mar 2023 TARA

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

07:14 22 Mar 2023 TARA

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More

The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

11:17 22 Mar 2023 TARA

Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

08:00 22 Mar 2023 TARA

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in fireside chats at two upcoming virtual conferences:

08:00 22 Mar 2023 TARA

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022.

05:57 22 Mar 2023 TARA

TARA Stock: Why The Price Increased This Past Week

The stock price of Protara Therapeutics Inc (NASDAQ: TARA) increased by over 5% during intraday trading. This is why it happened.

10:26 22 Mar 2023 TARA

Biopharma Stock Skyrockets on FDA Approval

Biopharmaceutical stock Protara Therapeutics Inc (NASDAQ:TARA) is surging today, up 11.9% to trade at $7.55 at last check.

09:43 22 Mar 2023 TARA

Why Protara Therapeutics Stock Is Rising Today

Protara Therapeutics Inc (NASDAQ: TARA) is trading higher Tuesday after the company announced FDA clearance of the Investigational New Drug application for TARA-002 for the treatment of non-muscle invasive bladder cancer. Protara Therapeutics expects to begin a Phase 1 clinical trial of TARA-002 in adults with high-grade non-muscle invasive bladder cancer by the end of 2021.

TARA Financial details

Company Rating
Neutral
Market Cap
39.35M
Income
-65.95M
Revenue
0
Book val./share
9.07
Cash/share
7.49
Dividend
-
Dividend %
-
Employees
31
Optionable
No
Shortable
Yes
Earnings
03 May 2023
P/E
-1.12
Forward P/E
-
PEG
1.09
P/S
-
P/B
0.3
P/C
0.5
P/FCF
-1.47
Quick Ratio
26.06
Current Ratio
26.59
Debt / Equity
0.11
LT Debt / Equity
0.05
-
-
EPS (TTM)
-5.86
EPS next Y
-
EPS next Q
-
EPS this Y
-10.29%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
408.82%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
48.63%
Inst Trans
-1.69%
ROA
-25%
ROE
-25%
ROC
-0.26%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
11.31M
Shs Float
5.97M
-
-
-
-
Target Price
-
52W Range
2.378-5.71
52W High
-25.8%
52W Low
+85.5%
RSI
59
Rel Volume
6.75
Avg Volume
21.25K
Volume
143.31K
Perf Week
34.42%
Perf Month
9.12%
Perf Quarter
3.92%
Perf Half Y
-1.59%
-
-
-
-
Beta
1.56785
-
-
Volatility
0.26%, 0.3%
Prev Close
0%
Price
3.71
Change
2.49%

TARA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-3.9-2.57-4.7-4.21-5.86
Operating cash flow per share
-4.37-2.68-3.24-3.07-2.35
Free cash flow per share
-4.39-2.68-3.36-3.12-2.36
Cash per share
4.111.0623.318.127.49
Book value per share
3.841.0927.5414.419.07
Tangible book value per share
3.841.0923.4611.799.07
Share holders equity per share
3.841.0927.5414.419.07
Interest debt per share
000.010.80.57
Market cap
483.07M95.84M175.13M75.82M30.18M
Enterprise value
463.7M89.66M7.62M47.33M12.43M
P/E ratio
-23.3-6.39-5.15-1.6-0.46
Price to sales ratio
00000
POCF ratio
-20.79-6.13-7.48-2.2-1.14
PFCF ratio
-20.69-6.12-7.21-2.16-1.14
P/B Ratio
23.6314.990.880.470.3
PTB ratio
23.6314.990.880.470.3
EV to sales
00000
Enterprise value over EBITDA
-22.49-6.09-0.23-1.04-0.19
EV to operating cash flow
-19.96-5.73-0.33-1.37-0.47
EV to free cash flow
-19.86-5.72-0.31-1.35-0.47
Earnings yield
-0.04-0.16-0.19-0.62-2.19
Free cash flow yield
-0.05-0.16-0.14-0.46-0.88
Debt to equity
0.150.090.020.070.11
Debt to assets
0.130.080.020.060.1
Net debt to EBITDA
0.940.424.960.630.27
Current ratio
7.5511.9658.1321.6615.01
Interest coverage
000-27.340
Income quality
1.121.040.690.730.4
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
000.150.170
Capex to operating cash flow
0.0100.040.020
Capex to revenue
00000
Capex to depreciation
-1.03-0.06-4.51-5.09-0.48
Stock based compensation to revenue
00000
Graham number
18.357.9553.9536.9434.57
ROIC
1.672.70.26-0.47-1.06
Return on tangible assets
-0.88-2.15-0.2-0.33-0.58
Graham Net
3.530.9622.777.216.5
Working capital
20.16M6.39M166.52M88.81M80.41M
Tangible asset value
20.44M6.39M169.73M132.4M102.08M
Net current asset value
20.16M6.39M165.52M82.43M74.94M
Invested capital
0000.040.06
Average receivables
000317K317K
Average payables
366K352K588.5K934K1.27M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1.01-2.35-0.17-0.29-0.65
Capex per share
-0.020-0.12-0.05-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
Revenue per share
00000
Net income per share
-0.91-0.96-0.76-0.68-3.46
Operating cash flow per share
-0.61-0.97-0.46-0.47-0.45
Free cash flow per share
-0.62-0.98-0.46-0.48-0.45
Cash per share
8.127.798.758.557.49
Book value per share
14.4113.5312.9212.359.07
Tangible book value per share
11.7810.9110.39.739.07
Share holders equity per share
14.4113.5312.9212.359.07
Interest debt per share
0.640.660.610.610.57
Market cap
75.84M57.49M32.98M33.35M30.18M
Enterprise value
47.35M39.08M5.98M-7.55M12.43M
P/E ratio
-1.85-1.34-0.97-1.08-0.19
Price to sales ratio
00000
POCF ratio
-10.98-5.24-6.44-6.24-6
PFCF ratio
-10.91-5.24-6.41-6.14-6
P/B Ratio
0.470.380.230.240.3
PTB ratio
0.470.380.230.240.3
EV to sales
00000
Enterprise value over EBITDA
-4.65-3.8-0.71.19-0.31
EV to operating cash flow
-6.86-3.57-1.171.41-2.47
EV to free cash flow
-6.81-3.56-1.161.39-2.47
Earnings yield
-0.13-0.19-0.26-0.23-1.29
Free cash flow yield
-0.09-0.19-0.16-0.16-0.17
Debt to equity
0.070.060.060.070.11
Debt to assets
0.060.060.060.060.1
Net debt to EBITDA
2.81.793.186.460.44
Current ratio
21.6631.728.9426.5915.01
Interest coverage
0-26.520-29.10
Income quality
0.681.020.60.70.13
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.170.180.190.20
Capex to operating cash flow
0.01000.020
Capex to revenue
00000
Capex to depreciation
-0.81-0.2-0.38-0.080.01
Stock based compensation to revenue
00000
Graham number
17.1817.0614.8513.7826.57
ROIC
-0.1-0.1-0.1-0.15-0.62
Return on tangible assets
-0.07-0.08-0.07-0.06-0.34
Graham Net
7.217.027.917.746.5
Working capital
88.81M87.83M97.6M94.96M80.41M
Tangible asset value
132.4M122.72M115.94M109.66M102.08M
Net current asset value
82.43M81.67M91.67M89.25M74.94M
Invested capital
0.040.050.050.050.06
Average receivables
317K581K264K190K190K
Average payables
941K747.5K466.5K424K1.02M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.06-0.07-0.06-0.06-0.38
Capex per share
000-0.010

TARA Frequently Asked Questions

What is Protara Therapeutics, Inc. stock symbol ?

Protara Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol TARA

What is Protara Therapeutics, Inc. stock quote today ?

Protara Therapeutics, Inc. stock price is $3.71 today.

Is Protara Therapeutics, Inc. stock public?

Yes, Protara Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap